 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Lipoatrophy & HIV: Treatment
Overview
- A Clinical Overview of Poly-L-Lactic Acid (Sculptra, New-Fill) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Sculptra (Formerly New Fill) for Facial Wasting -- Where to Find Information on the Patient-Assistance Program (December 31, 2004)
In AIDS Treatment News, from AIDS Treatment News - Cheek to Chic: Lipoatrophy Treatments Compared (April 2004)
Brief summaries of three facial wasting treatments: New-Fill (called Sculptra in the United States), SilSkin and Bio-Alcamid.
In POZ - New Facial Filling Treatment for Lipodystrophy (September/October 2001)
How New-Fill works to help facial wasting.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
News
- FDA Approves Radiesse for Treating Facial Lipoatrophy (December 29, 2006)
From U.S. Food and Drug Administration - FDA Approves Radiesse Facial Filler for Two New Aesthetic Indications (December 27, 2006)
To read PDF, click here
From BioForm Medical, Inc. - Health Canada Provides Bio-Alcamid Injections for Facial Wasting; Full Approval Expected Soon (July 29, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Sculptra Costs Four Times More in U.S. Than in Europe (September 24, 2004)
In Washington Blade - Approval of Sculptra for Treating Facial Lipoatrophy (August 3, 2004)
From U.S. Food and Drug Administration - Lipoatrophy Treatment Nears Approval in U.S. (March 26, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - The FDA Has Accepted the Filing for an Injectable Poly-L-Lactic Acid Called "Sculptra" to Treat Facial Lipoatrophy (February 27, 2004)
The facial wasting treatment known outside the United States as New-Fill moves one step closer to U.S. approval.
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project - Aventis Applies for FDA Approval of Lipoatrophy Treatment (February 10, 2004)
The facial wasting treatment known most widely as New-Fill seeks review for possible approval in the United States.
From Advocate.com
Research
- Comparing the Effects of Rosiglitazone, Pravastatin, Recombinant Human Growth Hormone and Combinations Thereof on HIV-Associated Lipodystrophy (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Twice-Daily Massage Can Reduce Papule Formation Among HIV-Infected Patients Receiving Poly-L-Lactic Acid Injections (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - HIV JournalView: Exporting Lipodystrophy: d4T Usage in Developing World (July/August 2005)
From The Body PRO - Poly-L-Lactic Acid for the Treatment of Facial Wasting (April 2005)
A small study finds the injections are safe and reasonably well tolerated, but found no significant improvement in quality of life.
From The Body PRO - Bone Cement Injections Show Success as Facial Wasting Treatment (July 16, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Polylactic Acid Injections for Facial Wasting (November 2001)
In OUTReach, from San Francisco AIDS Foundation
  |
  |